United States Dollar Index weakens further amid correction in US bond yields
The US Dollar (USD) extends its decline against its major peers on Friday as United States (US) Treasury Yields correct after failing to extend the rally.
In the Asian trade, the US Dollar Index (DXY), which gauges the Greenback’s value against six major currencies, trades 0.1% lower to near 102.02. The DXY faced significant selling pressure on late Thursday after failing to extend the rally beyond its yearly high of 102.54 posted earlier this year. 10-year US Treasury Yields have retreated to near 5.23% from its Thursday’s high of 5.35%.
Yields on US-backed securities came under pressure as oil prices cut gains after President Donald Trump ruled out fears of renewed military activities against Iran till Mid-term elections.
“We [US] will not be attacking Iran at any time prior to the Midterm Elections to be held in the United States on November 3
Going forward, the major trigger for the US Dollar will be the US Consumer Price Index (CPI) data for September, which will be released on Wednesday. The inflation is expected to have a significant impact on Federal Reserve’s (Fed) interest rate expectations.
Currently, the CME FedWatch tool shows that financial markets have priced in at least one interest rate hike in the remainder of the year.
US Dollar Index Technical Analysis
In the daily chart, Dollar Index Spot trades at 102.03, holding above the 20-day exponential moving average (EMA) at 101.24, which suggests a bullish near-term bias with the trend underpinned by dynamic support. The Relative Strength Index (14) at 67.91 hovers just below overbought territory, hinting that upside momentum remains strong but may be entering a more mature phase where further gains could be slower or prone to brief pauses.
On the downside, initial support is located at the 20-day EMA at 101.24, where a decisive break would weaken the bullish structure and open the door to a deeper corrective phase toward prior price congestion zones. Looking up, the yearly high at 102.54 is the major hurdle.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
